PYC Therapeutics (ASX:PYC) reported Thursday that its loss per diluted share in the fiscal first half widened to AU$0.0549, from a loss of AU$0.04 per diluted share a year earlier.
Analysts polled by Visible Alpha were expecting a diluted loss per share of AU$0.03.
Revenue for the six months ended Dec. 31, 2024, was AU$12.7 million, up 39% from AU$9.1 million in the same period last year. Analysts surveyed by Visible Alpha expected AU$11.4 million in total revenue.
Analysts polled by Visible Alpha expect earnings of AU$0.10 per diluted share on revenue of AU$18.7 for the full fiscal year.
The firm did not pay or declare any dividends during the period.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。